KR20210068284A - A food composition for the improvement or prevention of asthma comprising extract of water dropwort - Google Patents
A food composition for the improvement or prevention of asthma comprising extract of water dropwort Download PDFInfo
- Publication number
- KR20210068284A KR20210068284A KR1020190157885A KR20190157885A KR20210068284A KR 20210068284 A KR20210068284 A KR 20210068284A KR 1020190157885 A KR1020190157885 A KR 1020190157885A KR 20190157885 A KR20190157885 A KR 20190157885A KR 20210068284 A KR20210068284 A KR 20210068284A
- Authority
- KR
- South Korea
- Prior art keywords
- asthma
- extract
- food composition
- food
- cells
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 76
- 235000013305 food Nutrition 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 240000008881 Oenanthe javanica Species 0.000 title claims abstract description 11
- 235000000365 Oenanthe javanica Nutrition 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 title abstract description 16
- 230000006872 improvement Effects 0.000 title description 6
- 230000002265 prevention Effects 0.000 title description 5
- 240000006243 Oenanthe sarmentosa Species 0.000 claims description 44
- 235000004199 Oenanthe sarmentosa Nutrition 0.000 claims description 44
- 235000003828 Sium suave Nutrition 0.000 claims description 44
- 229940117336 parsley extract Drugs 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 235000013361 beverage Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 11
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 235000013376 functional food Nutrition 0.000 abstract description 7
- 210000000265 leukocyte Anatomy 0.000 description 15
- 238000000605 extraction Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000013355 food flavoring agent Nutrition 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000004241 Th2 cell Anatomy 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 210000000621 bronchi Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 210000000447 Th1 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 235000020510 functional beverage Nutrition 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 3
- 229960004784 allergens Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241001674044 Blattodea Species 0.000 description 2
- 206010007522 Cardiac asthma Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- 208000005279 Status Asthmaticus Diseases 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 206010066392 Fear of death Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000208317 Petroselinum Species 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/23—Removal of unwanted matter, e.g. deodorisation or detoxification by extraction with solvents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 식물 추출물을 유효성분으로 포함하는 천식 예방 또는 개선용 식품조성물에 관한 것이다.The present invention relates to a food composition for preventing or improving asthma comprising a plant extract as an active ingredient.
2011년 기준 전 세계적으로 약 2억 3천 5백만 여명이 천식으로 고통을 받고 있는 것으로 알려져 있으며, 발병률은 환경에 따라서 많은 차이가 있으나, 전체 인구 대비 1% 내지 18%에 달하는 것으로 알려져 있다. 우리나라의 경우, 천식 유병률이 어린이에서는 1981년 5.6%에서 1990년 10.1%로 점차 증가하고 있으며, 성인에서도 천식환자가 증가되고 있는 것으로 조사되어, 특히 65세 이상의 노령 인구에서는 12.7% 높은 유병율을 보이고 있다.As of 2011, it is known that about 235 million people worldwide suffer from asthma, and the incidence rate varies greatly depending on the environment, but is known to reach 1% to 18% of the total population. In Korea, the prevalence of asthma in children is gradually increasing from 5.6% in 1981 to 10.1% in 1990, and it has been found that the number of asthma patients is also increasing in adults. .
상기 천식(asthma)은 발작성 호흡곤란을 반복적으로 나타내는 증상을 가지는 질환으로, 기관지 천식과 심장 천식이 있으며, 좁은 의미의 천식은 주로 기관지 천식을 의미한다. 상기 기관지 천식은 알레르기에 의한 대표적인 질환 중 하나로, 비만세포 표면의 IgE Fc 수용체에 결합하는 즉시과민항체(reagin)와 알레르겐(allergen)이 반응하여 화학물질을 유리시키며, 이에 따라 기도폐색이 일어나 발병하게 된다.Asthma is a disease having symptoms repeatedly showing paroxysmal dyspnea, and includes bronchial asthma and cardiac asthma, and asthma in a narrow sense mainly means bronchial asthma. The bronchial asthma is one of the representative diseases caused by allergy, and an immediate hypersensitivity antibody (reagin) and an allergen that bind to the IgE Fc receptor on the surface of mast cells react to liberate chemicals, and thus airway obstruction occurs. do.
상기 천식은 먼지진드기, 곰팡이나 바퀴벌레에 의한 감염, 애완동물의 털이나 오염물질과 같은 알레르기 유발물질 또는 흡연 등 다양한 원인에 의해 발병되는 것으로 알려져 있다.The asthma is known to be caused by various causes such as dust mites, infection by mold or cockroaches, allergens such as pet hair or pollutants, or smoking.
구체적으로, 상기 천식은 헬퍼 T 세포(helper T cell)와 밀접한 관련이 있는 면역관련 질환이다. 상기 헬퍼 T 세포는 분비를 유도하는 사이토카인(cytokine)의 종류에 따라, Th1 cell과 Th2 cell로 구분될 수 있다. 상기 Th1 cell은 주로 인터류킨-2(IL-2)나 인터페론-감마(IFN-γ)를 분비하고, 상기 Th2 cell은 IL-4, IL-5 및 IL-13을 분비한다. 또한, 상기 Th2 cell은 B 세포(B-cell)의 분화와 IgG가 IgE로 변화되는 것을 촉진하기도 한다. 상기 천식은 상기 Th1 cell과 Th2 cell의 균형이 파괴되어 발생하는 것으로 보고 되고 있다.Specifically, the asthma is an immune-related disease closely related to helper T cells. The helper T cells may be classified into Th1 cells and Th2 cells according to the type of cytokine that induces secretion. The Th1 cells mainly secrete interleukin-2 (IL-2) or interferon-gamma (IFN-γ), and the Th2 cells secrete IL-4, IL-5 and IL-13. In addition, the Th2 cell promotes the differentiation of B cells (B-cell) and the change of IgG to IgE. It has been reported that the asthma is caused by the destruction of the balance between the Th1 cells and the Th2 cells.
상기 천식은 면역관련 질환으로 다양한 사이토카인에 의해 유발 또는 억제될 수 있다. 보다 구체적으로, CD4 T 세포(CD4 T-cell)의 기능을 조절하는 것으로 알려진 IL-6는 천식 유도를 조절하는 것으로 알려져 있다. 반면에, IL-12는 Th1 cell과 Th2 cell의 균형을 조절하며, 천식의 억제와 관련이 있는 IFN-γ의 생산을 촉진하는 것으로 알려져 있다. 또한, IL-4와 IL-13은 염증과정의 진행, 기도과민반응, 점액분비 세포인 배상세포(goblet-cell)의 이상증식, 호산구 침윤, 점액 과분비 또는 B-cell 활성화에 관여하는 것으로 알려져 있으며, 천식발생의 주요인자로 보고되고 있다. 또한, IL-5는 호산구의 분화, 활성화 및 이동에 관여하며, 천식과 관련이 있는 것으로 알려져 있다.The asthma is an immune-related disease and may be induced or inhibited by various cytokines. More specifically, IL-6, which is known to modulate the function of CD4 T cells (CD4 T-cells), is known to modulate asthma induction. On the other hand, IL-12 regulates the balance of Th1 cells and Th2 cells, and is known to promote the production of IFN-γ, which is related to the inhibition of asthma. In addition, IL-4 and IL-13 are known to be involved in the progression of the inflammatory process, airway hyperactivity, abnormal proliferation of goblet-cells, mucin-secreting cells, eosinophil infiltration, mucus hypersecretion, or B-cell activation. , has been reported as a major factor in the development of asthma. In addition, IL-5 is involved in the differentiation, activation and migration of eosinophils, and is known to be associated with asthma.
상기 천식과 관련하여, 기존 치료방법으로 기관 확장제, 코르티코스테로이드(corticosteroid), 류코트리엔 조절제(leukotriene modifier), 테오필린(theophylline) 또는 항 IgE제가 제안되었으나, 이러한 치료제의 투여에도 불구하고 천식을 완벽히 치료하지 못하였으며, 몇몇 부작용에 대한 문제가 제기되고 있다. 일 예로, 구체적으로, 천식 치료제로 폭 넓게 이용되는 코르티코스테로이드 흡기제는 다양한 부작용이 보고되면서, 그 사용이 감소하고 있는 추세이다.In relation to the asthma, bronchodilators, corticosteroids, leukotriene modifiers, theophylline, or anti-IgE agents have been proposed as existing treatment methods, but despite the administration of these therapeutic agents, asthma cannot be completely cured. and some side effects have been raised. For example, in particular, as various side effects have been reported, corticosteroid inhalers, which are widely used as a treatment for asthma, have a tendency to decrease in use.
상기한 바와 같이, 상기 천식은 호흡기계와 관련된 난치성 면역질환으로, 치료를 위한 다양한 치료법이나 치료제와 관련된 연구가 진행되고 있으나, 각 치료제의 문제점 등으로 인해 그 사용이 제한되어있는 실정이다.As described above, asthma is an intractable immune disease related to the respiratory system, and various treatments or treatments for treatment are being studied, but their use is limited due to problems with each treatment.
특히, 의료비 증가에 따른 국가 부담가중, 노령화 사회 진입, 소비자의 건강관심 고조, 식품산업계의 신제품 개발 방향 등을 고려할 때, 자생식물과 같은 부작용 등의 문제가 적은 천연물 기반의 천식 개선 또는 예방을 위한 건강기능식품의 국내수요는 지속적으로 증가될 것으로 전망된다.In particular, when considering the burden of the national burden due to the increase in medical expenses, entry into an aging society, rising consumer health interest, and the direction of new product development in the food industry, natural product-based asthma improvement or prevention with fewer problems such as side effects such as native plants The domestic demand for health functional food is expected to increase continuously.
본 발명은 인체에도 무해한 천연물질을 유효성분으로 포함하는 천식 개선 또는 예방용 식품조성물을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a food composition for improving or preventing asthma comprising a natural substance that is harmless to the human body as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 미나리 추출물을 유효성분으로 포함하는 천식의 개선 또는 예방용 식품조성물을 제공한다. 상기 식품 조성물은 식품, 식품첨가제 또는 음료일 수 있으며, 바람직하게는 기능석 식품 조성물일 수 있다.In order to achieve the above object, the present invention provides a food composition for improving or preventing asthma comprising a water parsley extract as an active ingredient. The food composition may be a food, a food additive or a beverage, preferably a functional stone food composition.
상기 미나리 추출물은 탄소수 1 내지 5의 알코올, 물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나로 추출된 것 일 수 있고, 구체적으로 상기 미나리 추출물은 70% 에탄올 수용액으로 추출된 것일 수 있다.The water parsley extract may be one selected from the group consisting of alcohols having 1 to 5 carbon atoms, water, and mixtures thereof, and specifically, the water parsley extract may be extracted with a 70% aqueous ethanol solution.
또한, 본 발명은 상기 목적을 달성하기 위하여 미나리의 용도(Use), 구체적으로 미나리의 천식 개선 또는 예방용 용도를 제공한다.In addition, in order to achieve the above object, the present invention provides a use of water parsley, specifically, a use for improving or preventing asthma of water parsley.
본 명세서에서 특별한 언급이 없는 한, 유효성분이란 조성물, 구체적으로 식품조성물에 있어서 천식의 개선 또는 예방 효과를 제공하는 성분을 의미한다.Unless otherwise specified herein, the active ingredient refers to a component that provides an effect of improving or preventing asthma in a composition, specifically, a food composition.
본 발명의 발명자들은 부작용이 적고 투약이 쉬운 천연물질 중 천식의 개선 또는 예방 효과가 있는 천연물 유래의 물질을 찾기 위하여, 항천식 효과, 구체적으로, BALB/c 마우스(BALB/c mouse)에서 ovalbumin으로 기도 염증 및 기도 과민성(airway hyperresopnsiveness, AHR)을 유발한 천식 유도 동물 실험모델을 이용하여 항천식 효과를 확인한 결과, 미나리 추출물 특히, 미나리 70% 에탄올 수용액 추출물의 투여에 의하여, 폐기관지 세척액(bronchoalveolar lavage fluid, BALF) 중 총 백혈구(white blood cell, WBC) 수 등 면역세포 수의 변화에 대한 관찰 및 Ig E의 변화에 대한 관찰을 통해, 미나리(Oenanthe javanica) 70% 에탄올 수용액 추출물이 천식 개선 및 예방능이 우수한 것으로 평가되어, 이로부터 본 발명을 완성하였다.The inventors of the present invention, in order to find a substance derived from a natural product that has the effect of improving or preventing asthma among natural substances that have few side effects and are easy to administer, anti-asthma effect, specifically, ovalbumin in BALB/c mouse (BALB/c mouse) As a result of confirming the anti-asthma effect using an asthma-induced animal experimental model that induced airway inflammation and airway hyperresopnsiveness (AHR), the bronchoalveolar lavage extract (Bronchoalveolar lavage) Through observation of changes in the number of immune cells such as total white blood cells (WBC) in fluid, BALF, and changes in Ig E, water parsley ( Oenanthe javanica ) 70% ethanol aqueous solution extract improves and prevents asthma The performance was evaluated to be excellent, and the present invention was completed therefrom.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 미나리 추출물을 유효성분으로 포함하는 천식 개선 또는 예방용 식품조성물에 관한 것이다.The present invention relates to a food composition for improving or preventing asthma comprising a water parsley extract as an active ingredient.
상기 미나리(water dropwort, Oenanthe javanica)는 산형과의 다년생 초본으로써 우리나라 전역에서 자생하고 있으며 중국, 일본 등 아한대에서 열대에 이르는 지역에서 널리 분포하고 식용으로 재배하고 있다. 상기 미나리는 특유의 향긋함과 부드러운 식감이 특징인 식재료로, 다양한 음식의 재료로 사용되며, 여러 영양소가 풍부하고, 특히 해독작용이 뛰어나 체내 중금속이나 각종 독소를 배출하는데 탁월한 효과가 있어, 민간에서는 주로 변비 예방이나 음주 후 숙취 제거 등의 용도로 사용되기도 한다. 상기 미나리의 줄기는 20 내지 50cm 정도로 자라며 속이 비어있고 밑에서 가지가 많이 갈라져 옆으로 퍼진다. 상기 미나리의 잎은 어긋나게 달리며, 1회 또는 2회 우상으로 갈라진 겹잎으로 긴 잎자루가 있으나 위쪽으로 갈수록 짧아지고, 작은 잎은 난형으로 가장자리에 톱니가 있다. 상기 미나리의 꽃은 흰색으로, 7월 내지 9월에 원줄기 끝에서 복산형화서로 자잘하게 달리며, 꽃잎과 수술은 5개이다. 상기 미나리의 열매는 분과로 타원형이다.The water dropwort (water dropwort, Oenanthe javanica ) is a perennial herb of the umbel family that grows wild throughout Korea, and is widely distributed and cultivated for food in the boreal to tropical regions such as China and Japan. The water parsley is a food ingredient characterized by its unique fragrant and soft texture, and is used as a material for various foods. It is rich in various nutrients and has an excellent detoxification effect and has an excellent effect in discharging heavy metals and various toxins from the body. It is also used to prevent constipation or to get rid of a hangover after drinking. The stem of the water parsley grows to about 20 to 50 cm, is hollow, and branches are divided a lot from the bottom and spread to the side. The leaves of the water parsley run alternately, and have long petioles with compound leaves that are split once or twice to the upper right, but become shorter upwards. The flowers of the water parsley are white, and run finely in double inflorescences from the tip of the main stem in July to September, and have 5 petals and 5 stamens. The fruit of the water parsley is an oval-shaped segment.
상기 미나리는 그 형태에 특별한 제한이 없이 추출물 분야에서 추출물을 얻기 위하여 통상적으로 이용되는 형태를 모두 포함한다. 구체적으로, 상기 미나리는 미나리의 다양한 기관 또는 부분, 상세하게는 잎, 꽃, 뿌리, 줄기, 가지, 껍질, 및 종자일 수 있고, 일 예로 지상부, 또는 가식부인 잎, 줄기 및 이들의 혼합물로 이루어진 군 중에서 선택된 어느 하나, 일 예로 잎, 줄기 또는 이들의 혼합물일 수 있다.The water parsley includes all forms commonly used to obtain extracts in the field of extracts without any particular limitation on the form thereof. Specifically, the water parsley may be various organs or parts of water parsley, specifically leaves, flowers, roots, stems, branches, shells, and seeds, for example, consisting of leaves, stems, and mixtures thereof that are above-ground or edible parts. Any one selected from the group, for example, may be a leaf, a stem, or a mixture thereof.
상기 본 발명의 미나리 추출물은 추출용매로 추출하거나 추출용매로 추출하여 제조한 추출물에 분획용매를 가하여 분획하여 제조할 수 있다.The water parsley extract of the present invention can be prepared by extracting with an extraction solvent or by adding a fractionation solvent to an extract prepared by extraction with an extraction solvent.
상기 추출용매는 물 및 유기용매로 이루어진 군에서 선택된 1종 이상 일 수 있다. 상기 유기용매는 메탄올, 에탄올 등의 탄소수 1 내지 5의 알코올, 에틸아세테이트 또는 아세톤 등의 극성용매와 벤젠, 헥산 또는 디클로로메탄의 비극성용매 또는 이들의 혼합용매 일 수 있으며, 바람직하게는 탄소수 1 내지 5의 알코올, 물 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나, 더욱 바람직하게는 에탄올 수용액, 가장 바람직하게는 70% 에탄올 수용액일 수 있다.The extraction solvent may be at least one selected from the group consisting of water and organic solvents. The organic solvent may be an alcohol having 1 to 5 carbon atoms such as methanol or ethanol, a polar solvent such as ethyl acetate or acetone, and a non-polar solvent such as benzene, hexane or dichloromethane, or a mixed solvent thereof, preferably having 1 to 5 carbon atoms. Any one selected from the group consisting of alcohol, water and mixtures thereof, more preferably an aqueous ethanol solution, and most preferably a 70% aqueous ethanol solution.
상기 본 발명의 미나리 추출물은 통상의 식물 추출물, 구체적으로 식물 추출물의 제조방법에 따라 제조된 것일 수 있다. 보다 구체적으로, 불순물을 제거한 미나리에 추출용매를 가하고 추출과정을 수행하는 방법으로 수행할 수 있다. 상기 추출과정은 냉침추출법, 온침추출법, 가압추출법 또는 초음파 분쇄 추출법일 수 있다.The water parsley extract of the present invention may be prepared according to a conventional plant extract, specifically, a method for preparing a plant extract. More specifically, it can be carried out by adding an extraction solvent to water parsley from which impurities have been removed and performing the extraction process. The extraction process may be a cold needle extraction method, a warm needle extraction method, a pressure extraction method, or an ultrasonic pulverization extraction method.
상기 분획용매는 물, 부탄올, 에틸아세테이트, 클로로포름, 헥산 또는 이들의 혼합물일 수 있다. 상기 분획물은 상기 추출법으로 제조한 추출물, 구체적으로 조추출액에 분획과정을 더욱 실시한 분획물일 수 있다. 상기 분획용매는 에틸아세테이트, 에테르, 클로로포름, 벤젠, 헥산, 메틸렌클로라이드 및 이들의 혼합용매로 이루어진 군에서 선택된 용매일 수 있다. 상기 분획과정은 구체적으로 상기 조추출액에 헥산, 플로로포름, 에틸아세테이트, 부탄올 및 물을 순서로 가한 후에, 층 분리한 헥산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, 부탄올 분획물 및 물 분획물을 순차적으로 수득하는 방법으로 수행할 수 있다.The fractionation solvent may be water, butanol, ethyl acetate, chloroform, hexane, or a mixture thereof. The fraction may be an extract prepared by the above extraction method, specifically, a fraction obtained by further subjecting the crude extract to a fractionation process. The fractionation solvent may be a solvent selected from the group consisting of ethyl acetate, ether, chloroform, benzene, hexane, methylene chloride, and mixed solvents thereof. In the fractionation process, hexane, fluoroform, ethyl acetate, butanol and water were sequentially added to the crude extract, followed by layer-separated hexane fraction, chloroform fraction, ethyl acetate fraction, butanol fraction and water fraction were sequentially obtained can be done in this way.
상기 추출물 또는 분획물은 추출 또는 분획과정을 수행한 이후, 감압 여과 과정을 수행하거나 추가로 농축 및/또는 동결건조를 수행하여 농축하거나 용매를 제거할 수 있다. 상기 수득한 추출물은 사용시까지 급속 냉동 냉장고(deep freezer)에 보관할 수 있다.After performing the extraction or fractionation process, the extract or fraction may be concentrated or the solvent may be removed by performing a vacuum filtration process or further concentration and/or freeze-drying. The obtained extract may be stored in a deep freezer until use.
구체적으로, 상기 미나리 추출물은 상기 용매 추출 공정 후에 여과 공정, 농축 공정 및/또는 건조 공정을 선택적으로 또는 중복하여 추가 수행한 것일 수 있으며, 상기 여과공정은 여과지를 이용하여 수행할 수 있고, 상기 농축공정은 감압농축 등을 통하여 수행할 수 있으며, 상기 건조공정은 열풍건조 또는 냉동건조 등의 방법으로 수행할 수 있다.Specifically, the water parsley extract may be additionally performed by selectively or overlapping a filtration process, a concentration process and/or a drying process after the solvent extraction process, and the filtration process may be performed using filter paper, and the concentration The process may be carried out through reduced pressure concentration or the like, and the drying process may be carried out by a method such as hot air drying or freeze drying.
상기 미나리 추출물은 천식 유래 동물 실험모델을 통해 확인한 결과, 백혈구 수를 포함한 면역세포의 증가를 억제시키고, 폐의 조직병리학적 관찰 및 면역염색법을 통한 관찰 결과, 기관지와 혈관주변의 염증세포의 침윤 및 점액 분비를 유도하는 면역글로블린 E(Immuno Globulin E, IgE)의 생성을 억제함으로써, 천식의 개선 또는 예방 효과를 갖는 것으로 확인되었다.As a result of confirmation through an asthma-derived animal model, the water parsley extract inhibits the increase of immune cells including the number of white blood cells, and as a result of observation through histopathological observation and immunostaining of the lungs, the infiltration of inflammatory cells around the bronchial tubes and blood vessels and By suppressing the production of immunoglobulin E (Immuno Globulin E, IgE) that induces mucus secretion, it was confirmed to have an effect of improving or preventing asthma.
이러한 측면에서, 상기 미나리 추출물은 천식의 개선 또는 예방을 위한 용도로 사용될 수 있고, 상기 미나리 추출물은 천식의 개선 또는 예방용 식품조성물의 유효성분 또는 약리성분으로 사용될 수 있다.In this aspect, the water parsley extract can be used for the improvement or prevention of asthma, and the water parsley extract can be used as an active ingredient or a pharmacological component of a food composition for improving or preventing asthma.
본 발명에서 천식(asthma)이란 폐 속에 있는 기관지가 아주 예민해진 상태로, 때때로 기관지가 좁아져서 숨이 차고 가랑가랑하는 숨소리가 들리면서 기침을 심하게 하는 증상을 나타내는 질환을 의미하며, 기관지의 알레르기 염증 반응 때문에 발생하는 알레르기 질환이다. 상기 증상들은 반복적으로 또는 발작적으로 나타나며 유전적 요인과 환경적 요인이 합쳐져서 나타난다. 상기 천식은 기관지 천식과 심장 천식일 수 있으며, 좁은 의미로는 기관지 천식일 수 있다.Asthma in the present invention refers to a disease in which the bronchi in the lungs are very sensitive, and the bronchi are sometimes narrowed, causing shortness of breath and a severe coughing sound, and allergic inflammation of the bronchial tubes. It is an allergic disease caused by a reaction. The symptoms appear recurrently or episodic, and are a combination of genetic and environmental factors. The asthma may be bronchial asthma and cardiac asthma, and in a narrow sense may be bronchial asthma.
상기 기관지 천식의 대표적인 증상은 호흡곤란, 기침 또는 천명이다. 이러한 증상이 반복적으로 또는 발작적으로 나타나며, 실제 천식 환자는 상기와 같은 전형적인 천식의 증상 외에 비전형적인 증상을 호소하는 경우도 많다. 즉, 가슴이 답답하거나 흉부 압박감을 호소하는 경우 또는 목구멍에 가래가 걸려있는 것 같은 증상만을 호소하는 경우도 있다. 일반적으로, 감기에 걸린 후에 호흡곤란이 악화하거나, 달리기 같은 운동 후에 호흡곤란, 거친 숨소리 증상들이 많이 나타난다. 때로는 심한 천식 발작으로 즉각적인 응급치료 및 입원 치료가 절대적으로 필요한 경우가 있는데, 이때 환자는 곧 죽을 것 같은 공포를 느끼며, 실제로 심한 천식 발작은 생명을 위협하기도 한다.Typical symptoms of the bronchial asthma are shortness of breath, coughing or wheezing. These symptoms appear repeatedly or episodic, and in fact, asthma patients often complain of atypical symptoms in addition to the typical asthma symptoms as described above. In other words, there are cases where the chest is stuffy or the chest feels tight, or there are cases where only symptoms such as phlegm hanging in the throat are complained. In general, shortness of breath worsens after catching a cold, or after exercise such as running, shortness of breath and harsh breathing symptoms often appear. Sometimes, a severe asthma attack absolutely requires immediate emergency treatment and hospitalization. At this time, the patient feels the fear of death, and in fact, a severe asthma attack is life-threatening.
상기 천식의 원인은 유전적 요인과 환경적 요인이 있으며, 주로 이들의 상호작용에 의해 발병한다. 구체적으로, 부모로부터 물려받은 알레르기 체질과 주위의 천식유발 인자들이 상호 작용을 일으켜 면역체계에 혼란이 생기면서 천식이 발생하게 된다.The cause of asthma is genetic and environmental factors, and is mainly caused by their interaction. Specifically, the allergic constitution inherited from parents interacts with surrounding asthma-inducing factors, causing confusion in the immune system and causing asthma.
천식을 유발하는 요인으로는 원인 물질과 악화 요인이 있다. 상기 원인 물질을 알레르겐(allergen)이라고 하는데, 대표적인 알레르겐은 집먼지 진드기, 꽃가루, 동물의 털이나 비듬 또는 바퀴벌레 등이 있다. 상기 악화 요인은, 감기, 담배연기와 실내오염, 대기오염, 식품첨가제, 과격한 운동 등 신체적 활동, 기후 변화, 황사, 스트레스 등이 있다.Factors that cause asthma include causative agents and exacerbating factors. The causative agent is called an allergen, and representative allergens include house dust mites, pollen, animal hair, dander, or cockroaches. The aggravating factors include a cold, cigarette smoke and indoor pollution, air pollution, food additives, physical activity such as extreme exercise, climate change, yellow dust, and stress.
천식, 특히 기관지 천식의 치료법으로는 증상이 있으면 신속하게 증상을 회복시키고 재발을 방지하기 위해서 질병을 조절하는 약제를 장기간 사용하는 약물요법과, 천식의 원인 물질을 찾아 원인 알레르겐 노출을 최소화하고 악화인자로부터 회피하는 회피요법이 있다.For the treatment of asthma, especially bronchial asthma, drug therapy is a long-term use of disease-controlling agents to quickly recover symptoms and prevent recurrence, and find substances that cause asthma to minimize exposure to causative allergens and reduce exacerbation factors. There are ways to avoid it.
상기 약물요법으로는 좁아진 기관지를 짧은 시간 내에 완화시키는 기관지 확장제와 같은 증상 완화제와 기관지의 알레르기 염증을 억제하여 천식발작을 예방 또는 개선하는 질병 조절제로 구분한다. 상기 증상 완화제의 경우, 부작용의 문제는 적은 편이나 근본적인 개선 효과를 발휘할 수 없고, 상기 질병 조절제의 경우 호르몬 제제 등이어서 부작용이 문제가 되고 있다.The drug therapy is classified into a symptom reliever such as a bronchodilator that relieves narrowed bronchi within a short time, and a disease control agent that prevents or improves asthma attacks by suppressing allergic inflammation of the bronchi. In the case of the symptom reliever, the problem of side effects is small, but the fundamental improvement effect cannot be exerted. In the case of the disease control agent, the side effect is a problem because it is a hormone preparation.
본 발명의 천식 예방 또는 치료용 조성물은, 조성물 총 중량에 대하여 상기 미나리를 0.001 내지 99.99중량%, 바람직하게는 0.1 내지 99 중량%로 포함할 수 있으며, 상기 천식 예방 또는 치료용 조성물의 사용방법 및 사용목적에 따라 유효성분의 함량을 적절히 조절할 수 있다.The composition for preventing or treating asthma of the present invention may contain the water parsley in an amount of 0.001 to 99.99% by weight, preferably 0.1 to 99% by weight, based on the total weight of the composition, and the method of using the composition for preventing or treating asthma and The content of the active ingredient can be appropriately adjusted according to the purpose of use.
상기 조성물은 미나리 추출물 외에 부형제, 일 예로 영양제, 비타민, 전해질, 풍미제, 착색제, 중진제, 펙트산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 추가로 함유할 수 있다. 상기 조성물에는 상기 성분들이 독립적으로 또는 조합하여 추가될 수 있다. 상기 추가성분의 함량은 바람직하게는 상기 미나리 추출물 100 중량부 당 0.1 내지 20,000 중량부 범위에서 추가할 수 있다.In addition to the water parsley extract, the composition contains excipients, for example, nutrients, vitamins, electrolytes, flavoring agents, colorants, thickeners, pectic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid It may further contain a carbonation agent and the like used in beverages. The above components may be added to the composition independently or in combination. The content of the additional component may be preferably added in the range of 0.1 to 20,000 parts by weight per 100 parts by weight of the water parsley extract.
이러한 측면에서, 본 발명의 식품조성물은 상기 미나리 추출물을 유효성분으로 포함하고, 천식이나 천식 관련 질병의 개선 또는 예방 효과를 가진 식품조성물일 수 있다. In this aspect, the food composition of the present invention may be a food composition comprising the water parsley extract as an active ingredient, and having an effect of improving or preventing asthma or asthma-related diseases.
본 명세서에서 있어서, 식품이란 함은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서 식품, 식품 첨가제, 건강 기능성 식품 및 음료를 모두 포함하는 의도이다.In the present specification, the term “food” means a natural product or processed product containing one or more nutrients, and preferably means a state that can be eaten directly through a certain processing process, and has a conventional meaning As such, it is intended to include all foods, food additives, health functional foods and beverages.
본 발명의 미나리 추출물을 첨가할 수 있는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 기능성 식품 등이 있다. 추가로, 본 발명의 식품에는 특수영양식품(예, 조제유류, 영유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(예, 각종 김치류, 장아찌 등), 음료(예, 과실, 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면 스프 등)을 포함하나 이에 한정되지 않는다.Foods to which the water parsley extract of the present invention can be added include, for example, various foods, beverages, gum, tea, vitamin complexes, and functional foods. In addition, the food of the present invention includes special nutritional foods (eg, formula milk, infant food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), health supplements, seasoned foods (eg, , soy sauce, soybean paste, gochujang, mixed soy sauce, etc.), sauces, sweets (eg snacks), dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (eg various kimchi, pickles, etc.), beverages (eg, fruit and vegetable beverages, soy milk, fermented beverages, etc.) and natural seasonings (eg, ramen soup, etc.), but is not limited thereto.
상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다. The food, beverage or food additive may be prepared by a conventional manufacturing method.
본 발명에서 기능성 식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다.Functional food in the present invention is a food group or food composition that has added value to act and express the function of the food for a specific purpose using physical, biochemical, and bioengineering methods, etc. It refers to food that has been designed and processed to sufficiently express body control functions related to the body.
상기 기능성 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The functional food may include a food supplementary additive that is pharmaceutically acceptable, and may further include an appropriate carrier, excipient and diluent commonly used in the manufacture of functional food.
본 발명에서 음료란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며 기능성 음료를 포함하는 의도이다.In the present invention, beverage means a generic term for drinking to quench thirst or enjoy taste, and is intended to include functional beverages.
상기 음료는 지시된 비율로 필수 성분으로서 상기 미나리 추출물을 유효성분으로 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The beverage is not particularly limited in other ingredients other than containing the water parsley extract as an active ingredient as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage.
상기의 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 수크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of the above natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .
상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1 g 내지 20 g, 바람직하게는 5 g 내지 12 g이다. 그밖에 본 발명의 조성물은 천연 과일 주스, 과일 쥬스 음료, 야채 음료의 제조를 위한 과육을 추가로 함유할 수 있다.The proportion of the natural carbohydrate is generally about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the composition of the present invention. In addition, the composition of the present invention may further contain pulp for the production of natural fruit juice, fruit juice beverage, and vegetable beverage.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, organic acids, protection It may contain a sexual colloid thickener, a pH adjuster, a stabilizer, a preservative, glycerin, alcohol, a carbonation agent used in carbonated beverages, and the like.
이러한 성분을 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지 않지만, 본 발명의 미나리 추출물 100 중량부 당 0 내지 20,000 중량부 범위에서 선택될 수 있다.These components may be used independently or in combination. The proportion of these additives is not so important, but may be selected from 0 to 20,000 parts by weight per 100 parts by weight of the water parsley extract of the present invention.
본 발명에서 기능성 음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미한다. In the present invention, a functional beverage is a beverage group or beverage composition that has added value to act and express the function of the beverage for a specific purpose using physical, biochemical, and bioengineering methods, etc. It refers to a beverage designed and processed to sufficiently express body control functions related to recovery, etc.
상기 기능성 음료는 지시된 비율로 필수 성분으로서 본 발명의 미나리 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The functional beverage is not particularly limited in other ingredients except for containing the water parsley extract of the present invention as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage.
상기 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 수크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .
상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1 g 내지 20 g, 바람직하게는 5 g 내지 12 g일 수 있다.The proportion of the natural carbohydrate may be generally about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the composition of the present invention.
또한, 천식 개선 또는 예방을 목적으로 하는 식품 조성물에 있어서, 상기 미나리 추출물의 양은 전체 식품 중량의 0.01 중량% 내지 15 중량%로 포함할 수 있으며, 음료 조성물은 100 ㎖를 기준으로 0.02 g 내지 5 g, 바람직하게는 0.3 g 내지 1 g의 비율로 포함할 수 있다.In addition, in the food composition for the purpose of improving or preventing asthma, the amount of the water parsley extract may include 0.01% to 15% by weight of the total food weight, and the beverage composition is 0.02 g to 5 g based on 100 ml , Preferably it may be included in a ratio of 0.3 g to 1 g.
또한, 본 발명은 미나리 추출물의 용도(Use), 구체적으로 미나리의 천식 개선 또는 예방용 용도에 관한 것이다. 상기 미나리 추출물은 미나리 물 추출물일 수 있다.In addition, the present invention relates to the use of parsley extract, specifically, to the use of parsley for the improvement or prevention of asthma. The water parsley extract may be a water parsley extract.
상기 미나리 추출물, 구체적으로 미나리 물 추출물은 실험동물에 의한 천식 동물 모델을 통하여 확인한 결과, 백혈구 수의 증가를 억제시키고, 폐의 조직병리학적 관찰 및 면역염색법을 통한 관찰 결과, 기관지와 혈관주변의 염증세포의 침윤 및 점액 분비를 유도하는 IgE의 생성을 억제함으로써, 염증세포의 침윤 및 점액 분비를 억제할 수 있는 것으로 확인되어, 천식 또는 천식과 관련된 질환의 예방 또는 개선에 효과적인 것으로 예상되어, 천식이나 천식 관련 질환의 개선 또는 예방용 용도가 우수한 것으로 평가된다.The water parsley extract, specifically, water extract of water parsley, was confirmed through an asthma animal model by an experimental animal, and as a result, suppressed the increase in the number of white blood cells, and as a result of observation through histopathological observation of the lungs and immunostaining method, inflammation of the bronchial tubes and blood vessels. By inhibiting the production of IgE that induces cell infiltration and mucus secretion, it has been confirmed that it is possible to suppress the infiltration and mucus secretion of inflammatory cells, and is expected to be effective in the prevention or improvement of asthma or asthma-related diseases. It is evaluated that the use for improving or preventing asthma-related diseases is excellent.
본 발명의 미나리 추출물은 동물 실험을 통하여 확인한 결과, 백혈구 수의 증가를 억제시키고, 기관지와 혈관주변의 염증세포의 침윤 및 점액 분비를 억제하는 것으로 확인되었으며, 상기 유효성분인 미나리는 식품으로 이용되는 식물이므로, 이로부터 제조된 미나리 추출물은 부작용에 대한 문제도 없을 것으로 예상되어, 천식 등의 새로운 예방 또는 치료제로서 매우 가치가 높을 것으로 판단된다.As a result of confirmation through animal experiments, the water parsley extract of the present invention was confirmed to inhibit the increase in the number of white blood cells, and to inhibit the infiltration and mucus secretion of inflammatory cells around the bronchi and blood vessels, and the active ingredient, water parsley, is used as food. Since it is a plant, it is expected that the water parsley extract prepared therefrom will not have any problems with side effects, so it is judged to be very valuable as a new preventive or therapeutic agent such as asthma.
도 1은 본 발명의 일 실시예에 따른 백혈구 세포의 세포 수 변화를 나타낸 그래프로, 도 1a는 단위 부피당 백혈구 세포(WBC) 수(x103 cells/μL)를 나타낸 그래프이고, 도 1b는 단위 부피당 호중구 세포 또는 중성 백혈구(NE, Neutrophil) 수(x103 cells/μL)를 나타낸 그래프이며, 도 1c는 단위 부피당 호산구 세포 또는 산성 백혈구(EO, Eosinophil) 수(x103 cells/μL)를 나타낸 그래프이다. 또한, 상기 그래프의 가로축의 CON은 아무런 처리를 하지 않은 정상 대조군을 의미하고, OVA는 천식을 유발한 음성 대조군을 의미하며, DEX는 덱타메타손(dexamethasone)을 처리한 양성 대조군을 의미하고, 다른 표기는 각 종류의 미나리 추출물의 종류 및 함량을 처리한 실험군을 의미한다.
도 2는 본 발명의 일 실시예에 따른 천식 실험 모델을 이용한 동물 실험에서 폐조직의 병리조직학적인 변화를 기관지와 폐조직에서 확인한 면역글로블린 E(Immuno Globulin E, IgE)의 생성 억제여부를 확인한 그래프로, 상기 그래프의 가로축의 CON은 아무런 처리를 하지 않은 정상 대조군을 의미하고, OVA는 천식을 유발한 음성 대조군을 의미하며, DEX는 덱타메타손(dexamethasone)을 처리한 양성 대조군을 의미하고, 다른 표기는 각 종류의 미나리 추출물의 종류 및 함량을 처리한 실험군을 의미한다.1 is a graph showing the change in the cell number of leukocytes according to an embodiment of the present invention, FIG. 1a is a graph showing the number of white blood cells (WBC) per unit volume (x10 3 cells/μL), FIG. 1b is a graph showing the number of leukocytes per unit volume It is a graph showing the number of neutrophil cells or neutrophils (NE, Neutrophil) (x10 3 cells/μL), Figure 1c is a graph showing the number of eosinophil cells or acid leukocytes (EO, Eosinophil) per unit volume (x10 3 cells/μL) . In addition, CON on the horizontal axis of the graph means a normal control without any treatment, OVA means a negative control induced asthma, DEX means a positive control treated with dexamethasone, and other The label means the experimental group treated with the type and content of each type of water parsley extract.
FIG. 2 is a graph confirming whether the production of immunoglobulin E (Immuno Globulin E, IgE) is inhibited in the bronchial and lung tissues in an animal experiment using an asthma experimental model according to an embodiment of the present invention; FIG. , CON on the horizontal axis of the graph means a normal control without any treatment, OVA means a negative control induced asthma, DEX means a positive control treated with dexamethasone, and other The label means the experimental group treated with the type and content of each type of water parsley extract.
도 1은 본 발명의 일 실시예에 따른 백혈구 세포의 세포 수 변화를 나타낸 그래프로, 도 1a는 단위 부피당 백혈구 세포(WBC) 수(x103 cells/μL)를 나타낸 그래프이고, 도 1b는 단위 부피당 호중구 세포 또는 중성 백혈구(NE, Neutrophil) 수(x103 cells/μL)를 나타낸 그래프이며, 도 1c는 단위 부피당 호산구 세포 또는 산성 백혈구(EO, Eosinophil) 수(x103 cells/μL)를 나타낸 그래프이다. 또한, 상기 그래프의 가로축의 CON은 아무런 처리를 하지 않은 정상 대조군을 의미하고, OVA는 천식을 유발한 음성 대조군을 의미하며, DEX는 덱타메타손(dexamethasone)을 처리한 양성 대조군을 의미하고, 다른 표기는 각 종류의 미나리 추출물의 종류 및 함량을 처리한 실험군을 의미한다.1 is a graph showing the change in the cell number of leukocytes according to an embodiment of the present invention, FIG. 1a is a graph showing the number of white blood cells (WBC) per unit volume (x10 3 cells/μL), FIG. 1b is a graph showing the number of leukocytes per unit volume It is a graph showing the number of neutrophil cells or neutrophils (NE, Neutrophil) (x10 3 cells/μL), Figure 1c is a graph showing the number of eosinophil cells or acid leukocytes (EO, Eosinophil) per unit volume (x10 3 cells/μL) . In addition, CON on the horizontal axis of the graph means a normal control without any treatment, OVA means a negative control induced asthma, DEX means a positive control treated with dexamethasone, and other The label means the experimental group treated with the type and content of each type of water parsley extract.
도 2는 본 발명의 일 실시예에 따른 천식 실험 모델을 이용한 동물 실험에서 폐조직의 병리조직학적인 변화를 기관지와 폐조직에서 확인한 면역글로블린 E(Immuno Globulin E, IgE)의 생성 억제여부를 확인한 그래프로, 상기 그래프의 가로축의 CON은 아무런 처리를 하지 않은 정상 대조군을 의미하고, OVA는 천식을 유발한 음성 대조군을 의미하며, DEX는 덱타메타손(dexamethasone)을 처리한 양성 대조군을 의미하고, 다른 표기는 각 종류의 미나리 추출물의 종류 및 함량을 처리한 실험군을 의미한다.2 is a graph confirming whether the production of immunoglobulin E (Immuno Globulin E, IgE) is inhibited in the bronchial and lung tissues of the histopathological changes in the lung tissue in an animal experiment using an asthma experimental model according to an embodiment of the present invention; , CON on the horizontal axis of the graph means a normal control without any treatment, OVA means a negative control induced asthma, DEX means a positive control treated with dexamethasone, and other The label means the experimental group treated with the type and content of each type of water parsley extract.
Claims (4)
상기 미나리 추출물은 70%(v/v) 에탄올 수용액으로 추출된 것인 천식 개선 또는 예방용 식품조성물.The method of claim 1,
The water parsley extract is 70% (v / v) a food composition for improving or preventing asthma that is extracted with an aqueous solution of ethanol.
상기 식품 조성물은 식품, 식품첨가제 또는 음료인 것인 천식 예방 또는 개선용 식품 조성물.The method of claim 1,
The food composition is a food, food additive, or beverage for preventing or improving asthma.
상기 식품 조성물은 기능석 식품 조성물인 천식 예방 또는 개선용 식품 조성물.4. The method of claim 3,
The food composition is a functional stone food composition, a food composition for preventing or improving asthma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190157885A KR20210068284A (en) | 2019-12-01 | 2019-12-01 | A food composition for the improvement or prevention of asthma comprising extract of water dropwort |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190157885A KR20210068284A (en) | 2019-12-01 | 2019-12-01 | A food composition for the improvement or prevention of asthma comprising extract of water dropwort |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210068284A true KR20210068284A (en) | 2021-06-09 |
Family
ID=76415228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190157885A KR20210068284A (en) | 2019-12-01 | 2019-12-01 | A food composition for the improvement or prevention of asthma comprising extract of water dropwort |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20210068284A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050095380A (en) | 2004-03-26 | 2005-09-29 | 정종문 | Functional food composition showing anti-oxidative, anti-allergic rhinitis, anti-atopic dermatitis, anti-chronic asthma and anti-arthritic activity |
KR20070034561A (en) | 2007-03-08 | 2007-03-28 | 유홍구 | Thought Medicine |
KR101358405B1 (en) | 2013-08-21 | 2014-02-11 | (주)파라스 | Functional detergent composition |
KR101357225B1 (en) | 2013-08-21 | 2014-02-11 | (주)파라스 | Disposable water soluble stick detergent |
-
2019
- 2019-12-01 KR KR1020190157885A patent/KR20210068284A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050095380A (en) | 2004-03-26 | 2005-09-29 | 정종문 | Functional food composition showing anti-oxidative, anti-allergic rhinitis, anti-atopic dermatitis, anti-chronic asthma and anti-arthritic activity |
KR20070034561A (en) | 2007-03-08 | 2007-03-28 | 유홍구 | Thought Medicine |
KR101358405B1 (en) | 2013-08-21 | 2014-02-11 | (주)파라스 | Functional detergent composition |
KR101357225B1 (en) | 2013-08-21 | 2014-02-11 | (주)파라스 | Disposable water soluble stick detergent |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101817055B1 (en) | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities | |
KR20150086982A (en) | Composition comprising Polygala tenuifolia extract for preventing or treating atopic dermatitis | |
KR20150040392A (en) | undiluted stevia liquid and the berages, and its manufacturing method | |
KR20130020095A (en) | Hepatoprotective composition containing stauntonia hexaphylla extract | |
KR101486484B1 (en) | A food composition for the improvement or prevention of asthma comprising extract of allium hookeri | |
KR102180223B1 (en) | Anti-obesity composition comprising extract of Sargassum horneri | |
KR20180011021A (en) | Pharmaceutical composition comprising extract of Clematis apiifolia DC. or Silene armeria L. for treating or prventing inflammatory disease | |
US8980846B2 (en) | Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma | |
JP6444440B2 (en) | Method for producing akebi extract and functional food using the extract | |
KR20140034620A (en) | Composition for preventing or treating diabetbes mellitus disease containing extract of plants | |
KR101673204B1 (en) | Health beverage using natural materials with protection of brain cells | |
KR20220081301A (en) | Pharmaceutical composition for preventing or treating infalmmatory disease comprising glycyrrhiza glabra l. and orus alba l. | |
KR102252130B1 (en) | A composition for increasing functions of immune comprising natural extracts | |
KR20210068284A (en) | A food composition for the improvement or prevention of asthma comprising extract of water dropwort | |
KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
KR102147592B1 (en) | Composition for rerpessing smoking and health functional food containing the composition | |
KR101895024B1 (en) | Composition for Enhancement of Immunity | |
KR101141191B1 (en) | Functional food composition and pharmaceutical composition for the prevention and alleviation of allergy symptoms | |
KR20160022190A (en) | A composition for the treatment or prevention of asthma comprising erythronium japonicum | |
KR102542119B1 (en) | Composition for preventing or treating inflammatory airway diseases caused fine dust comprising syneilesis aconitifolia (bunge) maxim extract | |
KR20220142004A (en) | A food composition for the improvement or prevention of asthma comprising extract of ginseng berry | |
KR101769123B1 (en) | Cosmetic composition containing natural complex extract for improving atopic dermatitis | |
KR102604905B1 (en) | Composition for immune enhancing comprising sprout Angelica gigas extract | |
KR101624293B1 (en) | Composition for enhancing immune response comprising extract of Benincasa hispida Cogniaux or fermented extract of the same | |
KR20180006612A (en) | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof |